<DOC>
	<DOCNO>NCT00161590</DOCNO>
	<brief_summary>Primary Objective : - To determine toxicity profile tolerability alemtuzumab ( Campath ) administer combination cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) chemotherapy ( C-CHOP ) patient T-cell , null-cell NK-cell lymphoma . Secondary Objectives : - To evaluate response rate , overall survival , disease-free survival patient T-cell , null-cell , NK-cell lymphoma treat Campath + CHOP chemotherapy . - To assess incidence cytomegalovirus ( CMV ) reactivation patient lymphomas treat Campath + CHOP combination . - To determine feature might predictive resistance treatment predictive relapse , include absence glycosylphosphatidylinositol ( GPI ) -linked protein .</brief_summary>
	<brief_title>Study CHOP + Campath T-Cell , Null Cell , Natural Killer ( NK ) -Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patients must diagnosis nonBcell , nonHodgkin 's lymphoma ( include Tcell , nullcell , NKcell lymphoma , exclude lymphoblastic lymphoma ) Stage II , III , IV disease require chemotherapy At least one site measurable disease , 1.5 cm diameter great Age &gt; = 18 year Absolute granulocyte count least 1500 cells/mm3 , unless neutropenia due marrow infiltration tumor Platelet count least 100,000 cells/mm3 unless thrombocytopenia due marrow infiltration tumor Creatinine le 2 x upper limit normal ( ULN ) Total bilirubin le 2 x ULN ( dose reduce vincristine adriamycin require bilirubin &gt; 1.2 mg/dL ) Echocardiogram ( Echo ) multiple gate acquisition scan ( MUGA ) document normal ejection fraction prior chemotherapy Able give inform consent Known central nervous system ( CNS ) involvement Known HIV disease Patients pregnant nursing Any factor might limit patient 's ability provide inform consent Life expectancy &lt; 3 month Patients unwilling agree use effective mean birth control treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>NK cell lymphoma</keyword>
	<keyword>Null cell lymphoma</keyword>
</DOC>